Although significant improvements have been made in the outcomes of children with cancer,
the pace of improvement has slowed in recent years as the limits of therapy intensification …

Abstract The Zero Childhood Cancer Program is a precision medicine program to benefit
children with poor-outcome, rare, relapsed or refractory cancer. Using tumor and germline …

MAPPYACTS (NCT02613962) is an international prospective precision medicine trial
aiming to define tumor molecular profiles in pediatric patients with recurrent/refractory …

Simple Summary Precision medicine is a revolutionary new way to deliver cancer treatment
by targeting specific genetic changes of the cancer of the individual child with the goal of …

To evaluate the clinical impact of molecular tumor profiling (MTP) with targeted sequencing
panel tests, pediatric patients with extracranial solid tumors were enrolled in a prospective …

Abstract The third multistakeholder Paediatric Strategy Forum organised by ACCELERATE
and the European Medicines Agency focused on immune checkpoint inhibitors for use in …

The use of targeted small-molecule therapeutics and immunotherapeutics has been limited
to date in pediatric oncology. Recently, the number of pediatric approvals has risen, and …

Background Germline genome sequencing in childhood cancer precision medicine trials
may reveal pathogenic or likely pathogenic variants in cancer predisposition genes in more …

PURPOSE The cancer research community is constantly evolving to better understand
tumor biology, disease etiology, risk stratification, and pathways to novel treatments. Yet the …

Simple Summary Medulloblastoma is the commonest malignant brain tumour of childhood.
Disease relapse following maximal multi-modal therapy including upfront craniospinal …